drugset
drugset / Trial / NCT01855867

HIV Non-Occupational Post-Exposure Prophylaxis

NCT01855867 ↗

Phase 4 Completed 100 enrolled Kenneth H. Mayer, MD Gilead Sciences · collab
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to see if an anti-HIV medication known as Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir DF) is safe, tolerable and acceptable when taken for 28 days, once a day after a possible, sexual, exposure to the Human Immune Deficiency Virus (HIV).

Timeline

Start
2013-05
Primary completion
2014-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cobicistat Small molecule 150 mg Oral
Subject Tenofovir disoproxil fumarate Small molecule 300 mg Oral
Subject elvitegravir Small molecule 150 mg Oral
Subject emtricitabine Other / unclassified 200 mg Oral

Indications

HIV infectious disease